|Day Low/High||86.90 / 87.01|
|52 Wk Low/High||19.62 / 87.01|
Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Juno Therapeutics, Inc.
Lundin Law PC announces a class action lawsuit has been filed against Juno Therapeutics Inc.
Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, announced today that it has acquired RedoxTherapies, Inc.
Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors who purchased Juno Therapeutics, Inc.
Crude oil kept markets under pressure on Wednesday after erasing big gains achieved over the previous session.
Here's a technical look at how to trade some of the most active stocks on the market right now.
Stocks are mixed Wednesday after the latest reading on the U.S. economy shows a steady state of growth.
Stocks struggle to determine direction on Wednesday as Wall Street takes a slight pause after two days of record-making runs.
Juno Therapeutics (JUNO) stock is surging in early-morning trading as a result of the FDA lifting the clinical hold placed on 'its lead pivotal trial' that resulted in two deaths.
Juno Therapeutics shares are soaring following news that a study of an experimental treatment for leukemia has been allowed to resume.
Stock futures make smaller moves higher on Wednesday as Wall Street takes a pause after two days of record-making runs.
Juno Therapeutics allowed to resume drug trial while Valeant's largest shareholder exits.
U.S. Stocks are taking a breather after hitting fresh record highs this week.
U.S. stock futures are rising slightly Wednesday following Tuesday's action that saw U.S. benchmarks finish at record highs.
Maybe investors aren't so gung-ho after three days of gains and record closes.
Five days after the federal agency had halted the clinical trial, the Seattle biopharma company said it will testing the leukemia drug candidate.
Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced that the U.
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible securities law violations by certain officers and directors of Juno Therapeutics Inc.
Hagens Berman Sobol Shapiro LLP alerts investors in Juno Therapeutics Inc.
Wall Street closed out the holiday-shortened week with a bang. Stocks bagged major gains after a blowout jobs report brought relief over the state of the U.S. economy.
Stocks jump Friday after a blockbuster jobs report assures investors recent weakness was an aberration.
Shares of Juno Therapeutics (JUNO) will bounce back from hitting extreme lows after its clinical study on a chemotherapy drug was halted, RBC's Michael Yee said on CNBC today.
U.S. stocks jumped after the latest reading on the U.S. labor market brought relief over the strength of the economy.
Levi & Korsinsky announces it has commenced an investigation of Juno Therapeutics Inc.
Stocks jump Friday morning after the latest reading on the U.S. labor market brings relief over the strength of the economy.
Juno Therapeutics’ (JUNO) stock rating was cut to ‘neutral’ from ‘overweight’ at JPMorgan after the biopharma company’s clinical trial was put on hold after patient deaths.
Stock futures move higher on Friday morning after the latest read on the U.S. labor market shows 287,000 jobs added to the U.S. economy in June.
Here are Friday's top research calls, including an upgrade for CF Industries, and downgrades for Citigroup, Juno Therapeutics and AT&T.
Juno Therapeutics reminds investors yet again that the business of biotech -- developing new medicines that are effective and reasonably safe -- is hard to get right.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.